<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006455" GROUP_ID="MOVEMENT" ID="548006102509294142" MERGED_FROM="" MODIFIED="2009-05-08 16:46:03 +0200" MODIFIED_BY="Ema Roque" NOTES="&lt;p&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2009-04-26 13:23:44 +0100" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="" REVMAN_SUB_VERSION="5.0.18" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.0">
<COVER_SHEET MODIFIED="2009-03-17 04:54:55 +0000" MODIFIED_BY="Tiago Mestre">
<TITLE>Therapeutic interventions for disease progression in Huntington's disease</TITLE>
<CONTACT>
<PERSON ID="9CC9BE5C82E26AA2012C734C85CBB923" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Tiago</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Mestre</LAST_NAME>
<SUFFIX/>
<POSITION>Neurology Resident</POSITION>
<EMAIL_1>tmestre@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Neurological Clinical Research Unit</DEPARTMENT>
<ORGANISATION>Institute of Molecular Medicine</ORGANISATION>
<ADDRESS_1>Hospital de Santa Maria</ADDRESS_1>
<ADDRESS_2>Av. Prof. Egas Moniz</ADDRESS_2>
<CITY>Lisboa</CITY>
<ZIP>1649-028</ZIP>
<REGION/>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<PHONE_1>+351 917532125</PHONE_1>
<PHONE_2/>
<FAX_1>+ 351 217802129</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2009-03-17 04:54:55 +0000" MODIFIED_BY="Tiago Mestre">
<PERSON ID="9CC9BE5C82E26AA2012C734C85CBB923" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Tiago</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Mestre</LAST_NAME>
<SUFFIX/>
<POSITION>Neurology Resident</POSITION>
<EMAIL_1>tmestre@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Neurological Clinical Research Unit</DEPARTMENT>
<ORGANISATION>Institute of Molecular Medicine</ORGANISATION>
<ADDRESS_1>Hospital de Santa Maria</ADDRESS_1>
<ADDRESS_2>Av. Prof. Egas Moniz</ADDRESS_2>
<CITY>Lisboa</CITY>
<ZIP>1649-028</ZIP>
<REGION/>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<PHONE_1>+351 917532125</PHONE_1>
<PHONE_2/>
<FAX_1>+ 351 217802129</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6005" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Joaquim</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Ferreira</LAST_NAME>
<SUFFIX/>
<POSITION>Co-ordinator, Cochrane Movement Disorders Group</POSITION>
<EMAIL_1>movementdisord@fm.ul.pt</EMAIL_1>
<EMAIL_2/>
<URL>http://www.fm.ul.pt/Movement-disorders</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Laboratório de Farmacologia Clínica e Terapêutica</DEPARTMENT>
<ORGANISATION>Faculdade de Medicina de Lisboa</ORGANISATION>
<ADDRESS_1>Hospital de Santa Maria</ADDRESS_1>
<ADDRESS_2>Av. Prof. Egas Moniz</ADDRESS_2>
<CITY>Lisboa</CITY>
<ZIP>1649-028</ZIP>
<REGION/>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<PHONE_1>+ 351 21 797 3453</PHONE_1>
<PHONE_2/>
<FAX_1>+ 351 21 780 2129</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14797" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Miguel</FIRST_NAME>
<MIDDLE_INITIALS>M</MIDDLE_INITIALS>
<LAST_NAME>Coelho</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>movementdisord@mail.telepac.pt</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Laboratório de Farmacologia Clínica e Terapêutica</DEPARTMENT>
<ORGANISATION>Faculdade de Medicina de Lisboa</ORGANISATION>
<ADDRESS_1>Av. Prof. Egas Moniz</ADDRESS_1>
<ADDRESS_2/>
<CITY>Lisboa</CITY>
<ZIP>1649-028</ZIP>
<REGION/>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<PHONE_1>+ 351 21 797 34 53</PHONE_1>
<PHONE_2/>
<FAX_1>+ 351 21 781 96 88</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="87E9223582E26AA20104C58E72B84E4C" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Mário</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Rosa</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1/>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Neurological Clinical Research Unit</DEPARTMENT>
<ORGANISATION>Institute of Molecular Medicine</ORGANISATION>
<ADDRESS_1>Centro de Estudos Egas Moniz</ADDRESS_1>
<ADDRESS_2>Faculdade de Medicina de Lisboa, Av. Prof. Egas Moniz</ADDRESS_2>
<CITY>Lisboa</CITY>
<ZIP>1649-028</ZIP>
<REGION/>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<PHONE_1>+ 351 21 7930629</PHONE_1>
<PHONE_2/>
<FAX_1>+ 351 21 7957474</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6111" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Cristina</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Sampaio</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>movementdisord@fm.ul.pt</EMAIL_1>
<EMAIL_2>movementdisord@mail.telepac.pt</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Laboratório de Farmacologia Clínica e Terapêutica</DEPARTMENT>
<ORGANISATION>Faculdade de Medicina de Lisboa</ORGANISATION>
<ADDRESS_1>Hospital de Santa Maria</ADDRESS_1>
<ADDRESS_2>Av. Prof. Egas Moniz</ADDRESS_2>
<CITY>Lisboa</CITY>
<ZIP>1649-028</ZIP>
<REGION/>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<PHONE_1>+ 351 21 797 34 53</PHONE_1>
<PHONE_2/>
<FAX_1>+ 351 21 780 2129</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2009-01-19 03:43:15 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Minor update: 20/07/08&lt;/p&gt;" NOTES_MODIFIED="2009-01-19 03:43:15 +0000" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="23" MONTH="12" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="23" MONTH="12" YEAR="2007"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="10" MONTH="1" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2007"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="11" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="23" MONTH="12" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Movement disorders Cochrane Review Group</NAME>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Neurological Clinical Research Unit, Institute of Molecular Medicine</NAME>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-04-26 13:23:44 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2009-01-19 02:53:58 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2009-01-12 16:49:10 +0000" MODIFIED_BY="[Empty name]">Interventions to delay progression of Huntington's disease</TITLE>
<SUMMARY_BODY MODIFIED="2009-01-19 02:53:58 +0000" MODIFIED_BY="[Empty name]">
<P>Huntington´s disease (HD) is an autosomal dominant neurodegenerative disease for which no cure is currently available. We proposed to assess the effectiveness of interventions aimed at modifying disease progression and evaluate the methodological quality of the corresponding clinical trials. We selected eight trials comprising a total of 1366 participants. The results show that no intervention demonstrated an effect in modifying disease progression in HD.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-04-26 13:23:44 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2009-01-19 02:50:37 +0000" MODIFIED_BY="[Empty name]">
<P>Huntington's disease (HD) is an autosomal dominant neurodegenerative disease with an average onset between the fourth and fifth decade of life; it leads to death 15 to 20 years after the onset of symptoms. Although several drugs seem effective in controlling the incapacitating manifestations of HD, no specific therapy is known. The present review aims at analysing the best available data on therapeutic interventions investigated with the goal of modifying the progression of the disease as measured in terms of survival, disability or progression of HD core symptoms.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-01-19 02:50:55 +0000" MODIFIED_BY="[Empty name]">
<P>Evaluate the effectiveness of therapeutic interventions aimed at modifying disease progression in HD.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-01-19 02:51:08 +0000" MODIFIED_BY="[Empty name]">
<P>The search strategy developed for the Movement Disorders Group was undertaken. The Cochrane Controlled Trials Register, Medline, EMBASE and Clinical Trials Database of the United States National Institute of Health were thoroughly searched until December 2007.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-01-19 02:51:56 +0000" MODIFIED_BY="[Empty name]">
<P>All randomised, double-blinded, placebo-controlled clinical trials of therapeutics investigated with the goal of modifying disease progression in HD were included. Participants should have genetically confirmed diagnosis of HD or compatible symptoms and a family history. Trials had a follow-up duration of more than three months and at least ten participants. All pharmacological and non-pharmacological interventions were included.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-01-19 02:52:42 +0000" MODIFIED_BY="[Empty name]">
<P>Two reviewers independently assessed the eligibility of identified trials. The methodological quality was assessed and eligible data were registered onto standardised forms. An intention-to-treat analysis was conducted, when feasible. If data were not available in the original publication, the principal investigator of the trial was contacted for further information. A meta-analysis was to be conducted when possible; otherwise, a descriptive summary of the results was provided. The software Revman 5.0.15 was used for statistical analysis.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-01-19 02:53:26 +0000" MODIFIED_BY="[Empty name]">
<P>Eight trials were included involving a total of 1366 HD patients. The duration of the studies ranged between 30 and 144 weeks (median: 52 weeks). The following interventions were selected: vitamin E, Idebenone, Baclofen, Lamotrigine, creatine, coenzyme Q10 + Remacemide, ethyl-eicosapentanoic acid and Riluzole. No trials produced positive results for the selected efficacy outcome measures. A descriptive summary of the trials is provided. The selected interventions were found to be generally safe and well tolerated.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-04-26 13:23:44 +0100" MODIFIED_BY="[Empty name]">
<P>Only pharmacological interventions were included and none proved to be effective as a disease-modifying therapy for HD. Further trials with greater methodological quality should be conducted using more sensitive biological markers. Pre-symptomatic mutation carriers should be included in future studies.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-04-26 12:59:39 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2009-01-19 02:56:42 +0000" MODIFIED_BY="[Empty name]">
<P>Huntington's disease (HD) also known as Huntington's chorea was first described by the eponymous North American physician George Huntington in 1872 (<LINK REF="REF-Lanska-1995" TYPE="REFERENCE">Lanska 1995</LINK>). It is characterised by choreiform movements, progressive dementia and psychiatric manifestations (depression, psychosis, apathy, irritability). Choreiform movements consist of involuntary, rapid, irregular, jerky motor actions including facial twitching or writhing and twitching of distal extremities and more generalised forms that impair gait (<LINK REF="REF-Ropper-2005" TYPE="REFERENCE">Ropper 2005</LINK>).<BR/>
<BR/>HD is an autosomal dominant inherited disease meaning that the child of an affected patient has a 50% chance of developing the disease. The causative gene is present on chromosome 4 and encodes a protein known as huntingtin (<LINK REF="REF-TH-s-DCR-Group-1993" TYPE="REFERENCE">TH s DCR Group 1993</LINK>). This protein gradually accumulates within brain cells causing damage and cell death in certain brain areas, specifically, the basal ganglia and neocortex. The rate of huntingtin accumulation is associated with the number of repeats of a specific sequence of three nucleic acids (CAG repeats). A greater number of repeats are associated with an earlier disease onset (<LINK REF="REF-Kieburtz-1994" TYPE="REFERENCE">Kieburtz 1994</LINK>).</P>
<P>HD is found throughout the world and in all ethnic groups. Global prevalence of HD is estimated to be 4-5 per one million people. In western countries it is estimated to be 8-10 per 100.000 people. There is no gender predominance. HD usually begins between the age of 30 and 50 and leads to death 15 to 20 years after the onset of neurological symptoms(<LINK REF="REF-Ropper-2005" TYPE="REFERENCE">Ropper 2005</LINK>). An early onset variant exists (Juvenile HD or Westphal variant) and typically begins in adolescence. In contrast with the adult-onset form, it presents with particular motor features of slowness of movement (bradykinesia) and increased muscular tone (rigidity type). Additionally, Juvenile HD has a more severe course with an average survival time of 5 to 10 years (<LINK REF="REF-Ropper-2005" TYPE="REFERENCE">Ropper 2005</LINK>).</P>
<P>No specific pharmacological therapy is known for HD. It is also known that some drugs seem to be active in controlling some of its major troublesome symptoms (chorea, psychosis, depression) (<LINK REF="REF-Bonelli-2004" TYPE="REFERENCE">Bonelli 2004</LINK>). Although it is difficult to separate a disease-modifying effect from a pure symptomatic one, the present review aims at covering the best quality data available about therapeutic interventions studied with the goal of modifying disease progression as measured with survival, disability or progression of functional impairment.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-01-19 02:57:05 +0000" MODIFIED_BY="[Empty name]">
<P>Evaluation of the effectiveness of therapeutic interventions aimed at modifying disease progression in HD</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-04-26 12:38:24 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2009-04-26 12:29:21 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2009-04-11 21:24:33 +0100" MODIFIED_BY="[Empty name]">
<P>All trials investigated were randomised controlled parallel clinical trials of therapeutics investigated with the goal of modifying disease progression in HD. In addition, all trials had a follow-up duration of more than three months and more than ten patients. Crossover trials were only included if the results of the first part of the trial before crossing-over were accessible.<BR/>
</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2009-01-19 02:58:06 +0000" MODIFIED_BY="[Empty name]">
<P>Participants should have had a genetically confirmed diagnosis of HD or the presence of clinical features of HD and a positive HD family history. All disease variants and all ages of disease-onset were included, as well as all possible concomitant therapies.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-11-13 02:32:18 +0000" MODIFIED_BY="[Empty name]">
<P>All pharmacological and non-pharmacological interventions used with the objective of modifying disease progression in HD, including brain surgery (fetal neural transplants or other neurosurgical procedures).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-04-26 12:29:21 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2009-04-26 12:28:56 +0100" MODIFIED_BY="[Empty name]">
<P>The time to a clinically relevant disease stage considered as a consensual clinical marker of disease progression was used for primary outcome. The most definite clinical endpoint is death (or survival). Alternatives accepted were: neuropsychiatric symptoms onset, diagnosis of dementia, postural instability, falls, wheelchair confinement, bedridden status, retirement on grounds of ill-health or loss of autonomy. These outcomes could be measured as a binary variable or as time-to-event variable.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2009-04-26 12:29:21 +0100" MODIFIED_BY="[Empty name]">
<P>The considered outcome measure was decline in functional capacity as measured by a validated or consensually used scale. Other alternatives were symptomatic progression regarding the three main symptom complex of HD, specifically: progression of motor signs, progression of neuropsychiatric symptoms and progression of cognitive decline, all measured by validated scales or scales accepted by consensus. Safety outcomes measures were also considered, specifically: 1) tolerability measured by withdrawal from trials and 2) safety measured by the incidence and type of adverse effects, the occurrence of adverse effects leading to withdrawal and serious adverse effects defined as any adverse event that is life-threatening or results in death, hospitalisation or prolonged incapacity/disability.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-04-26 12:31:55 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2009-04-26 12:31:55 +0100" MODIFIED_BY="[Empty name]">
<P>The review was drawn on the search strategy developed for the Movement Disorders Group as a whole. We identified relevant trials in the following electronic databases:</P>
<OL>
<LI>Cochrane Controlled Trials Register (Central/CCTR in The Cochrane Library, Issue 4, 2007);</LI>
<LI>MEDLINE (1966 to December 2007);</LI>
<LI>EMBASE (1974 to December 2007);</LI>
<LI>Clinical Trials Database of the United States National Institute of Health (December 2007)</LI>
</OL>
<P>For MEDLINE and Cochrane Controlled Trials Register, a MeSH search using the following search strategy was conducted:<BR/>1.Huntington/all subheadings<BR/>2.diet therapy<BR/>3.drug therapy<BR/>4.prevention and control<BR/>5.rehabilitation<BR/>6.surgery<BR/>7.therapy<BR/>8.psychology<BR/>9.mortality<BR/>10.#1 AND #2<BR/>11.#1 AND #3<BR/>12.#1 AND #4<BR/>13.#1 AND #5<BR/>14.#1 AND #6<BR/>15.#1 AND #7<BR/>16.#1 AND #8<BR/>17.#1 AND #9<BR/>18.10-17<BR/>19.#18 AND Limit: clinical trial<BR/>20. in humans<BR/>
</P>
<P>No language restriction was applied. If necessary, the translation of the original article to Portuguese was done.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2009-01-19 03:01:42 +0000" MODIFIED_BY="[Empty name]">
<P>We also:</P>
<OL>
<LI>Searched reference lists of identified trials and HD review articles;</LI>
<LI>Hand searched the Movement Disorders Journal and abstract books of international congresses of movement disorders and dementia;</LI>
<LI>Personally contacted other researchers in the field;</LI>
<LI>Contacted drug manufactures to obtain additional information on trials identified in other sources or unpublished trials.</LI>
</OL>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-04-26 12:38:24 +0100" MODIFIED_BY="[Empty name]">
<P>Two reviewers (Mestre T, Ferreira J) independently assessed selection criteria in the identified studies. Disagreements concerning inclusion were resolved by consensus between the two reviewers and a third party (Coelho M).</P>
<P>The selected studies were independently assessed for methodological quality according to the Cochrane Collaboration handbook (<LINK REF="REF-Cochrane-2008" TYPE="REFERENCE">Cochrane 2008</LINK>). A record was made of the following items: randomisation methods, treatment and assessment blinding, comparability of treatment groups in terms of demographic and clinical characteristics (age of onset, disease duration and severity, CAG repeat expansion, co-morbidity, concomitant medication), inclusion and exclusion criteria, number of drop-outs or lost to follow-up and corresponding causes, duration of follow-up, definition of outcomes, use of validated scales and description of adverse events. The Jadad score was used as a global measure for methodological quality (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>). We excluded trials with a Jadad score &lt;3.</P>
<P>Possible sources of bias were taken into consideration, namely: 1) selection bias, including randomisation and random difference between groups due to a small sample size; 2) performance bias; 3) attrition bias; 4) detection bias, including modifications to validated rating scales; 5) selective reporting of results.</P>
<P>Eligible data were independently registered onto standardised forms by two reviewers (Mestre T, Ferreira J) and cross-checked for accuracy. Disagreements regarding inclusion were resolved by consensus between reviewers (Mestre T, Ferreira J) and a third party (Coelho M). An intention-to-treat analysis was conducted, whenever feasible. Thus data concerning the number of patients with each outcome event in each allocated treatment group was thoroughly sought, regardless of compliance and irrespective of patient ineligibility or exclusion after randomisation. If data were not available in the original publications, the principal investigator of the trial was contacted for further information. When considered relevant, the effect of missing outcomes from patients excluded after randomisation was evaluated by a best- and worst-case sensitivity analysis</P>
<P>The various rating scales used were dichotomised using each author's own criteria for benefit or no benefit. If these criteria were not described, benefit was defined as any delay in disease progression; no benefit was defined as the absence of a delay in disease progression. To dichotomise results, individual patient data were requested if the results were presented as mean values for groups. Thus, if possible, the results were reported as odds ratios with 95 % confidence intervals. Outcomes presented as time-to-event data were analysed using a logrank analysis (<LINK REF="REF-Cochrane-2008" TYPE="REFERENCE">Cochrane 2008</LINK>). The results were expressed as a Hazard Ratio (HR) with 95 % confidence intervals.</P>
<P>A meta-analysis was conducted if feasible. For time-to-event data, a modified Peto odds ratio fixed-effect method was used. For dichotomous data, the Peto odds ratio fixed-effect method was adopted (<LINK REF="REF-Cochrane-2008" TYPE="REFERENCE">Cochrane 2008</LINK>). Heterogeneity between trial results was tested using a standard chi-squared test (p &lt; 0.05). A descriptive summary of the results is provided since it was not possible to pool outcome data from different studies. A subgroup analysis for CAG repeat number was considered but not performed due to the reduced number of trials with this information. Statistical analysis was performed using the statistical tools incorporated in the software Revman 5.0.15 (<LINK REF="REF-Revman-2008" TYPE="REFERENCE">Revman 2008</LINK>)<BR/>
</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-04-26 12:54:46 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2009-04-26 12:46:03 +0100" MODIFIED_BY="[Empty name]">
<P>Eight trials were included comparing various pharmacological interventions with placebo in a total of 1366 HD patients. The initial search strategy resulted in 26 studies (1583 HD patients) appearing as eligible from the available information extracted from the corresponding titles and abstracts. Later, trials were excluded on the basis of open label design (n = 13; 178/11 % of patients), absence of control (n = 1; 7 HD patients), crossover design (n = 1; 10 HD patients), small sample, i.e., n &lt; 10 (n = 1; 7 HD patients) and phase I study (n = 2; 15 HD patients) (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). All surgical interventions were excluded due to an open label design.</P>
<SUBSECTION>
<HEADING LEVEL="3">TRIAL DESIGN:</HEADING>
<P>The eight included trials were randomised, placebo-controlled, double blind studies with a parallel design. One trial had a factorial design with three arms with different combinations of two active interventions and one with placebo (<LINK REF="STD-CARE_x002d_HD" TYPE="STUDY">CARE-HD</LINK>). Four trials were conducted in a single centre (<LINK REF="STD-Peyser-CE" TYPE="STUDY">Peyser CE</LINK>; <LINK REF="STD-Ranen-NG" TYPE="STUDY">Ranen NG</LINK>; <LINK REF="STD-Shoulson-I" TYPE="STUDY">Shoulson I</LINK>; <LINK REF="STD-Verbessem-P" TYPE="STUDY">Verbessem P</LINK>) and the remaining trials were conducted in a multicentric fashion. The patients included in the trials received treatment or placebo during 30 to 144 weeks (median: 52 weeks). All trials were published between 1989 and 2007 in the English language.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">PARTICIPANTS:</HEADING>
<P>In the included trials, the age of the participants had a median value of 45.5, ranging from 39.4 to 49.8 years of age. The disease duration had a median value of 5.1, ranging from 2.9 to 8.0 years. In two trials there was no data concerning age of participants (<LINK REF="STD-Peyser-CE" TYPE="STUDY">Peyser CE</LINK>) and/or disease duration (<LINK REF="STD-Peyser-CE" TYPE="STUDY">Peyser CE</LINK>; <LINK REF="STD-Puri-BK" TYPE="STUDY">Puri BK</LINK>). A confirmatory genetic diagnosis (CAG repeat) was only available in four trials (<LINK REF="STD-CARE_x002d_HD" TYPE="STUDY">CARE-HD</LINK>; <LINK REF="STD-EHDN" TYPE="STUDY">EHDN</LINK>; <LINK REF="STD-Kremer-B" TYPE="STUDY">Kremer B</LINK>; <LINK REF="STD-Puri-BK" TYPE="STUDY">Puri BK</LINK>) with the median value being 45 CAG repeats in both treatment and placebo groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">INTERVENTIONS:</HEADING>
<P>The following interventions were found: Baclofen (<LINK REF="STD-Shoulson-I" TYPE="STUDY">Shoulson I</LINK>), coenzyme Q10+Remacemide (<LINK REF="STD-CARE_x002d_HD" TYPE="STUDY">CARE-HD</LINK>), creatine (<LINK REF="STD-Verbessem-P" TYPE="STUDY">Verbessem P</LINK>) , ethyl-eicosapentanoic acid (<LINK REF="STD-Puri-BK" TYPE="STUDY">Puri BK</LINK>), Idebenone (<LINK REF="STD-Ranen-NG" TYPE="STUDY">Ranen NG</LINK>), Lamotrigine (<LINK REF="STD-Kremer-B" TYPE="STUDY">Kremer B</LINK>), Riluzole (<LINK REF="STD-EHDN" TYPE="STUDY">EHDN</LINK>), vitamin E (<LINK REF="STD-Peyser-CE" TYPE="STUDY">Peyser CE</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">OUTCOME MEASURES:</HEADING>
<P>Outcome measures changed across trials. The most frequently used primary outcome measure was a change in functional capacity using the Total Function Capacity (TFC)-UHDRS (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>) (<LINK REF="STD-CARE_x002d_HD" TYPE="STUDY">CARE-HD</LINK>; <LINK REF="STD-Kremer-B" TYPE="STUDY">Kremer B</LINK>; <LINK REF="STD-Shoulson-I" TYPE="STUDY">Shoulson I</LINK>). The remaining trials defined as primary outcome measure the control of motor symptoms, namely chorea, using the reduced form of the UHDRS-motor component, Total Motor Score-4 (TMS-4) (<LINK REF="STD-Puri-BK" TYPE="STUDY">Puri BK</LINK>) or an improvement in muscle strength expressed as the change in static and dynamic torque (<LINK REF="STD-Verbessem-P" TYPE="STUDY">Verbessem P</LINK>). Two trials used composite outcomes, Activity of Daily Living (ADL)-UHDRS and Quantified Neurological Examination (QNE) (<LINK REF="STD-Ranen-NG" TYPE="STUDY">Ranen NG</LINK>), and a combined score of the TMS and TFC of UHDRS (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>) (<LINK REF="STD-EHDN" TYPE="STUDY">EHDN</LINK>). The primary outcome was not clearly stated in one trial (<LINK REF="STD-Peyser-CE" TYPE="STUDY">Peyser CE</LINK>). No trial used a time-to-event variable as an outcome measure.</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-04-26 12:47:19 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">RANDOMISATION:</HEADING>
<P>In three trials a comprehensive description of the methodology used in randomisation could be found. The following methods were used: random number table (Peyser CE), computer-generated stratification by investigator (CARE-HD) and computer-generated stratification by centre (EHDN). Three trials failed to give a complete description in the original article, stating only the use of stratification by age and stage of illness (Shoulson I), blocking and stratification (Puri BK) and stratification by age and gender (Kremer B). In one trial, the authors considered a quasi-randomisation classification since randomisation was not followed until the completion of patients´ recruitment (Verbessem P).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">ALLOCATION:</HEADING>
<P>Allocation was adequately concealed in four trials (<LINK REF="STD-EHDN" TYPE="STUDY">EHDN</LINK>; <LINK REF="STD-Kremer-B" TYPE="STUDY">Kremer B</LINK>; <LINK REF="STD-Puri-BK" TYPE="STUDY">Puri BK</LINK>; <LINK REF="STD-Verbessem-P" TYPE="STUDY">Verbessem P</LINK>). The remaining trials were unclear about allocation concealment (<LINK REF="STD-CARE_x002d_HD" TYPE="STUDY">CARE-HD</LINK>; <LINK REF="STD-Peyser-CE" TYPE="STUDY">Peyser CE</LINK>; <LINK REF="STD-Ranen-NG" TYPE="STUDY">Ranen NG</LINK>; <LINK REF="STD-Shoulson-I" TYPE="STUDY">Shoulson I</LINK>). The authors decided to include the latter trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">SAMPLE SIZE CALCULATION:</HEADING>
<P>Sample size calculation procedures were described in seven trials (<LINK REF="STD-CARE_x002d_HD" TYPE="STUDY">CARE-HD</LINK>; <LINK REF="STD-EHDN" TYPE="STUDY">EHDN</LINK>; <LINK REF="STD-Kremer-B" TYPE="STUDY">Kremer B</LINK>; <LINK REF="STD-Peyser-CE" TYPE="STUDY">Peyser CE</LINK>; <LINK REF="STD-Puri-BK" TYPE="STUDY">Puri BK</LINK>; <LINK REF="STD-Ranen-NG" TYPE="STUDY">Ranen NG</LINK>; <LINK REF="STD-Shoulson-I" TYPE="STUDY">Shoulson I</LINK>). In one trial (<LINK REF="STD-Verbessem-P" TYPE="STUDY">Verbessem P</LINK>) a <I>post-hoc</I> sample size analysis was conducted.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">DATA INCLUDED:</HEADING>
<P>Five trials performed data analysis on an intention-to-treat basis exclusively (<LINK REF="STD-CARE_x002d_HD" TYPE="STUDY">CARE-HD</LINK>; <LINK REF="STD-Kremer-B" TYPE="STUDY">Kremer B</LINK>; <LINK REF="STD-Ranen-NG" TYPE="STUDY">Ranen NG</LINK>; <LINK REF="STD-Verbessem-P" TYPE="STUDY">Verbessem P</LINK>). In two trials (<LINK REF="STD-EHDN" TYPE="STUDY">EHDN</LINK>; <LINK REF="STD-Puri-BK" TYPE="STUDY">Puri BK</LINK>) both an intention-to-treat and a per-protocol analysis were performed. For these only the results from the intention-to-tract analysis were included as defined in the methodology. In two trials (<LINK REF="STD-Peyser-CE" TYPE="STUDY">Peyser CE</LINK>; <LINK REF="STD-Shoulson-I" TYPE="STUDY">Shoulson I</LINK>), only a per-protocol inclusion of data was performed. The contact with the authors was unfruitful.<BR/>
</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-04-26 12:54:46 +0100" MODIFIED_BY="[Empty name]">
<P>Unless otherwise indicated, results are expressed as mean±standard deviation.</P>
<P>In the trial of <LINK REF="STD-Peyser-CE" TYPE="STUDY">Peyser CE</LINK> with Vitamin E, 3000 UI/day, n = 81, at the end of one year of follow-up a deterioration of the main outcome variables was observed, although in a non significant fashion: 1. Quality of life as measured by the ADL scale of the Baltimore HD project (-2.2 ± 7.3 treatment group vs. -1.1 ± 7.6 placebo group; p = 0.55); 2. motor evaluation as measured by the QNE (-2.9 ± 11.8 treatment group vs. -2.3 ± 7.5 placebo group; p = 0,78) and 3. cognitive function as measured by the Mini-Mental Status Examination (MMSE) score (1.2 ± 3.5 treatment group vs. 0.0 ± 2.6 placebo group; p = 0,1). A <I>post-hoc</I> analysis of the patients with better baseline motor performance score (QNE &#8804; 45) tended to improve slightly with vitamin E (p = 0.02).</P>
<P>In a trial with Idebenone, 270 mg/day, n = 100, (<LINK REF="STD-Ranen-NG" TYPE="STUDY">Ranen NG</LINK>) no treatment effect was observed for the primary outcome variables: 1. ADL-UHDRS (2.9 ± 3.3 treatment group  vs. 3.1 ± 4.9 placebo group; p = NS) and 2. QNE (4.9 ± 7.5 treatment group vs. 5.1 ± 5.0 placebo group; p = NS) and motor impairment scale, a sub-component of QNE (1.4 ± 2.0 treatment group  vs. 1.6 ± 2.0 placebo group; p = NS). No treatment effect was observed in cognitive measures: MMSE, Buschke Selective Reading test, Benton Visual Retention test, Grooved Pegboard, Wechsler Adult Intelligence Scale (WAIS), Trail Making test and Stroop test. A cohort with the less affected patients (QNE &lt; 45) was also analysed and produced similar non-significant differences between treatment and placebo groups.</P>
<P>The trial with Baclofen, 60 mg/day, n = 60, (<LINK REF="STD-Shoulson-I" TYPE="STUDY">Shoulson I</LINK>) produced no significant change in the modified TFC (mTFC)-UHDRS between groups when comparing baseline to the end of trial at 30 weeks (-2.13 ± 1.61 treatment group vs. 1.32 ± 1.16 placebo group; p = NS). In fact, a trend toward a deleterious effect of Baclofen on the yearly change of the mTFC score was reported: 0.85 ± 0.64 treatment group vs. 0.53 ± 0.46 placebo group; p = 0.053. However, controlling data for age, stage of disease and inheritance pattern resulted in non significant results (p = 0.14).</P>
<P>In the trial with Lamotrigine 400 mg/day, n = 64 (<LINK REF="STD-Kremer-B" TYPE="STUDY">Kremer B</LINK>), a deterioration of functional capacity, both in treatment and placebo groups, was observed as measured by TFC-UHDRS (-1.89 ± 2.46 treatment group  vs. 2.11 ± 1.99 placebo group; p = NS). Similarly, no difference between groups was found in the median QNE: 13.5 (range: 8-17) treatment group vs. 17 (range: 4-42) placebo group; p = 0.84. However, a trend toward a beneficial effect in median chorea reduction was reported: 2.5 (range: 1-16) treatment group vs. 4 (range: 2-19) placebo group; p = 0.08. No significant difference between groups was found in the pre-selected neuropsychiatric measures (MMSE, Wechsler Adult Intelligence Scale-Revised (WAIS-R), WMS, Paired associates, paragraph recall, word fluency tests and Beck Depression Inventory) as well as in Klove Grooved Pegboard, finger-tapping tests.<BR/>
<BR/>In the trial of <LINK REF="STD-Verbessem-P" TYPE="STUDY">Verbessem P</LINK> studying creatine 5 g/day, n = 42, an improvement of muscular strength was assessed using as primary outcome the measurement of static and dynamic force. Other measures were used: bimanual coordination skill and cardiorespiratory fitness. No significant difference between groups was found, as well as in UHDRS scales of motor function, cognitive function and functional capacity.</P>
<P>In a trial with coenzyme Q10 and/or Remacemide, 300-600 mg/day and/or 400-600 mg/day, n = 347 (<LINK REF="STD-CARE_x002d_HD" TYPE="STUDY">CARE-HD</LINK>), no treatment effect was found in terms of a decrease in the deterioration of functional capacity as measured by TFC-UHDRS: 0.35 (95 % CI: -0.12, 0.82) coenzyme Q10 group vs. 0.00 (95 % CI: -0.47, 0.47) Remacemide group. However, coenzyme Q10 showed a nominally significant effect in slowing functional decline as measured by the functional assessment checklist of UHDRS (22 % slowing, p = 0.02). A trend was also found for a smaller decline in the TFC-UHDRS among coenzyme Q10-treated patients when compared with coenzyme Q10 non-treated patients (2.4 ± 2.14 coenzyme Q10-treated patients vs. 2.74 ± 2.28 coenzyme Q10 non-treated patients; p = 0.15). A trend toward a beneficial effect of coenzyme Q10 was also reported for behaviour (p = 0.08) and cognitive tests (Stroop test word reading (p = 0.09) and colour naming (p = 0.01), and the brief test of attention (p = 0.02). In the Remacemide group, a similar report was made for chorea using the motor scale of UHDRS (p = 0.06).</P>
<P>In the trial conducted by <LINK REF="STD-Puri-BK" TYPE="STUDY">Puri BK</LINK> (n = 135) no effect of ethyl-eicosapentanoic acid 2 g/day, was observed in the primary outcome measure: change in the TMS-4 (UHDRS) at 12 months. Similar results were obtained for the secondary outcome measures, i.e., the TMS-4 (UHDRS) at 6 months, the cognitive, behavioural, and functional scales of UHDRS and the Rockland Simpson Dysknesia Score. However, a per-protocol exploratory analysis produced a significant beneficial result in the TMS-4 (UHDRS) for ethyl-eicosapentanoic acid over placebo at 12 months (p = 0.046). An interaction of treatment with the number of CAG repeats was reported (p = 0.044) with better treatment effects for lower numbers of CAG repeat.</P>
<P>In the most recently published trial (<LINK REF="STD-EHDN" TYPE="STUDY">EHDN</LINK>) conducted with Riluzole, 100 mg/day, n = 537, no significant difference was found between groups for the primary outcome, i.e., the mean change of an algorithm-specified combined score of the TMS and TFC-UHDRS: 29.8 ± 26.8 treatment group vs. 28.2 ± 25.8 placebo group; p = 0.66. Presenting the scales separately produced similar results: TMS-UHDRS: 30.1 ± 28.6 treatment group vs. 28.3 ± 27.2 placebo group; p = NS. TFC-UHDRS: -4.6 ± 4.2 treatment group vs. 4.4 ± 4.1 placebo group, p = NS. No beneficial effect was observed using other outcome measures (chorea score, cognitive, behavioural, functional, independence and global clinical impression scales of UHDRS and Beck Depression Inventory).</P>
<P>All but three trials (<LINK REF="STD-Peyser-CE" TYPE="STUDY">Peyser CE</LINK>; <LINK REF="STD-Ranen-NG" TYPE="STUDY">Ranen NG</LINK>; <LINK REF="STD-Verbessem-P" TYPE="STUDY">Verbessem P</LINK>) reported adverse events. Regarding serious adverse events, they were reported in four trials (<LINK REF="STD-EHDN" TYPE="STUDY">EHDN</LINK>; <LINK REF="STD-CARE_x002d_HD" TYPE="STUDY">CARE-HD</LINK>; <LINK REF="STD-Kremer-B" TYPE="STUDY">Kremer B</LINK>; <LINK REF="STD-Puri-BK" TYPE="STUDY">Puri BK</LINK>), and two other reported the absence of serious adverse events (<LINK REF="STD-Ranen-NG" TYPE="STUDY">Ranen NG</LINK>; <LINK REF="STD-Shoulson-I" TYPE="STUDY">Shoulson I</LINK>). In two trials there was no reference to serious adverse events (<LINK REF="STD-Peyser-CE" TYPE="STUDY">Peyser CE</LINK>; <LINK REF="STD-Verbessem-P" TYPE="STUDY">Verbessem P</LINK>).</P>
<P>In the eight trials, there were a total of 164 (19%) drop-outs in the treatment group and 85 (17.4 %) in the placebo group. A special reference to the high number of drop-outs in the trial of Riluzole (<LINK REF="STD-EHDN" TYPE="STUDY">EHDN</LINK>),158 (29.4 %) out of 537 participants (treatment 106; control 52); 42 of those participants withdrew informed consent and 40 patients withdrew from study due to the initiation of anti-choreic medication. In terms of causes of drop-outs, in seven trials (<LINK REF="STD-CARE_x002d_HD" TYPE="STUDY">CARE-HD</LINK>; <LINK REF="STD-EHDN" TYPE="STUDY">EHDN</LINK>; <LINK REF="STD-Kremer-B" TYPE="STUDY">Kremer B</LINK>; <LINK REF="STD-Peyser-CE" TYPE="STUDY">Peyser CE</LINK>; <LINK REF="STD-Puri-BK" TYPE="STUDY">Puri BK</LINK>; <LINK REF="STD-Ranen-NG" TYPE="STUDY">Ranen NG</LINK>; <LINK REF="STD-Shoulson-I" TYPE="STUDY">Shoulson I</LINK>) drop-outs were due to adverse events in 43/164 cases in the treatment group with a median per-trial frequency of 40.0 % (range: 0-57.1 %) and in 12/85 cases in the placebo group with a median per-trial frequency of 14.3 % (range: 0-28.6 %). In one trial no comprehensive description of adverse events was found in the original article (<LINK REF="STD-Verbessem-P" TYPE="STUDY">Verbessem P</LINK>).</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-04-26 12:59:39 +0100" MODIFIED_BY="[Empty name]">
<P>None of the selected trials showed effectiveness for the defined primary outcome measures. However, in some trials non significant results closely achieving the pre-specified level of statistical significance were reported, and the authors defined those as trends. In the trial <LINK REF="STD-CARE_x002d_HD" TYPE="STUDY">CARE-HD</LINK> a trend of coenzyme Q10 for a reduced decline in functional capacity, cognitive and behaviour dimensions was reported, as well as a lesser slowing of functional capacity for the coenzyme Q10-treated patients was documented to be significant. These inconclusive preliminary results have prompted an additional trial to confirm or disclaim a potential beneficial effect of coenzyme Q10 that is ongoing (<LINK REF="STD-_x0032_CARE" TYPE="STUDY">2CARE</LINK>). In the trial by <LINK REF="STD-Puri-BK" TYPE="STUDY">Puri BK</LINK>, the authors reported a trend for the beneficial effect of ethyl-eicosapentanoic acid in TMS-4-UHDR, the selected primary outcome measure, but only in the per-protocol analysis. This was not confirmed in the intention-to-treat analysis. In fact, recent trials with ethyl-eicosapentanoic acid robustly showed a lack of effect for the same outcome measure after a 6-month treatment period (<LINK REF="REF-Miraxion_x002d_Europe" TYPE="REFERENCE">Miraxion-Europe</LINK>; <LINK REF="REF-TREND_x002d_HD" TYPE="REFERENCE">TREND-HD</LINK>).</P>
<P>Regarding the definition of outcome measures, the included trials only used variables defined as secondary outcome measures for the present systematic review, namely, decline in functional capacity or quality of life. Time-to-an-event variables were not integrated in the selected trials. Additionally, no trial focused on asymptomatic HD mutation carriers, who might be considered ideal candidates for studies assessing the delaying effect on disease onset or progression with a given intervention, as they will develop symptoms later in life. However, the discovery of more sensitive and specific biological markers is needed in HD, not only for a more sensitive and thus early clinical diagnosis, but also to decrease sample size in future clinical trials. These tools will provide a better means on determining the potential clinical benefit of newly discovered interventions. Research has been conducted in recent years to identify better markers of disease onset (<LINK REF="REF-Paulsen-JS" TYPE="REFERENCE">Paulsen JS</LINK>, <LINK REF="REF-TRACK_x002d_HD" TYPE="REFERENCE">TRACK-HD</LINK>).</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-04-11 22:14:27 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2009-04-11 22:14:09 +0100" MODIFIED_BY="[Empty name]">
<P>No intervention has proven a disease-modifying effect for Huntington's disease.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-04-11 22:14:27 +0100" MODIFIED_BY="[Empty name]">
<P>The current review emphasises the need to adapt trial design. Trials on asymptomatic HD mutation carriers are desirable. Improved clinimetric<I> </I>scales and biological markers for the assessment of disease progression are required in order to increase the sensitivity in which clinical trials capture a disease-modifying effect.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-01-12 15:08:41 +0000" MODIFIED_BY="[Empty name]"/>
<CONFLICT_OF_INTEREST>
<P> Mestre T, Ferreira J, Coelho M, Rosa MM were investigators in a clinical trial to investigate the efficacy of ethyl-eicosapentanoic acid for the treatment of HD.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-04-11 22:13:55 +0100" MODIFIED_BY="[Empty name]">
<P>Protocol - Ferreira J, Mestre T, Sampaio C.<BR/>Literature search - Ferreira J, Mestre T, Coelho M.<BR/>Literature selection - Ferreira J, Mestre T, Coelho M.<BR/>Papers quality assessment - Ferreira J, Mestre T.<BR/>Data collection from papers - Mestre T, Ferreira J.<BR/>Interpretation of data - Mestre T, Ferreira J, Coelho M, Rosa MM, Sampaio C.<BR/>Review writing - Mestre T, Ferreira J, Coelho M, Rosa MM, Sampaio C.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-01-19 03:40:22 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2008-12-04 04:41:27 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-CARE_x002d_HD" NAME="CARE-HD" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The Huntington study group</AU>
<TI>A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease</TI>
<SO>Neurology</SO>
<YR>2001</YR>
<VL>57(3)</VL>
<PG>397-404</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-EHDN" NAME="EHDN" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>European Huntington Disease Initiative Study Group</AU>
<TI>Riluzole in Huntington´s disease: a 3 year, randomised controlled study</TI>
<SO>Annals of Neurology</SO>
<YR>2007</YR>
<VL>62(3)</VL>
<PG>262-272</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kremer-B" NAME="Kremer B" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kremer B, Clark CM, Almqvist EW, Raymond LA, Graf P, Jacova C, et al</AU>
<TI>Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial</TI>
<SO>Neurology</SO>
<YR>1999</YR>
<VL>53(5)</VL>
<PG>1000-1011</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peyser-CE" NAME="Peyser CE" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peyser CE, Folstein M, Chase GA, Starkstein S, Brandt J, Cockrell JR, et al</AU>
<TI>Trial of d-alpha-tocopherol in Huntington's disease</TI>
<SO>Am J Psychiatry</SO>
<YR>1995</YR>
<VL>152(12)</VL>
<PG>1771-1775</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Puri-BK" NAME="Puri BK" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Puri BK, Leavitt BR, Hayden MR, Ross CA, Rosenblatt A, Greenamyre JT, et al</AU>
<TI>Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial</TI>
<SO>Neurology</SO>
<YR>2005</YR>
<VL>65(2)</VL>
<PG>286-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ranen-NG" NAME="Ranen NG" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ranen NG, Peyser CE, Coyle JT, Bylsma FW, Sherr M, Day L, et al</AU>
<TI>A controlled trial of idebenone in Huntington's disease</TI>
<SO>Mov Disord</SO>
<YR>1996</YR>
<VL>11(5)</VL>
<PG>549-554</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shoulson-I" NAME="Shoulson I" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shoulson I, Odoroff C, Oakes D, Behr J, Goldblatt D, Caine E, et al.</AU>
<TI>A controlled clinical trial of baclofen as protective therapy in early Huntington's disease</TI>
<SO>Ann Neurol</SO>
<YR>1989</YR>
<VL>25(3)</VL>
<PG>252-259</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Verbessem-P" NAME="Verbessem P" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Verbessem P, Lemiere J, Eijnde BO, Swinnen S, Vanhees L, Van Leemputte M, et al</AU>
<TI>Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial</TI>
<SO>Neurology</SO>
<YR>2003</YR>
<VL>61(7)</VL>
<PG>925-930</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-12-04 04:41:27 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bachoud_x002d_L_x00e9_vi-AC-_x0028_a_x0029_" MODIFIED="2008-12-04 04:35:58 +0000" MODIFIED_BY="[Empty name]" NAME="Bachoud-Lévi AC (a)" YEAR="2000">
<REFERENCE MODIFIED="2008-12-04 04:35:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bachoud-Lévi A, Bourdet C, Brugières P, Nguyen JP, Grandmougin T, Haddad B, Jény R, Bartolomeo P, Boissé MF, Barba GD, Degos JD, Ergis AM, Lefaucheur JP, Lisovoski F, Pailhous E, Rémy P, Palfi S, Defer GL, Cesaro P, Hantraye P, Peschanski M.</AU>
<TI>Safety and tolerability assessment of intrastriatal neural allografts in five patients with Huntington's disease</TI>
<SO>Exp Neurol</SO>
<YR>2000</YR>
<VL>161</VL>
<NO>1</NO>
<PG>194-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bachoud_x002d_L_x00e9_vi-AC-_x0028_b_x0029_" MODIFIED="2008-12-04 04:36:47 +0000" MODIFIED_BY="[Empty name]" NAME="Bachoud-Lévi AC (b)" YEAR="2000">
<REFERENCE MODIFIED="2008-12-04 04:36:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bachoud-Lévi AC, Rémy P, Nguyen JP, Brugières P, Lefaucheur JP, Bourdet C, Baudic S, Gaura V, Maison P, Haddad B, Boissé MF, Grandmougin T, Jény R, Bartolomeo P, Dalla Barba G, Degos JD, Lisovoski F, Ergis AM, Pailhous E, Cesaro P, Hantraye P, Peschanski M</AU>
<TI>Motor and cognitive improvements in patients with Huntington's disease after neural transplantation</TI>
<SO>Lancet</SO>
<YR>2000</YR>
<VL>356</VL>
<NO>9246</NO>
<PG>1975-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bachoud_x002d_L_x00e9_vi-AC-_x0028_c_x0029_" NAME="Bachoud-Lévi AC (c)" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bachoud-Lévi AC, Gaura V, Brugières P, Lefaucheur JP, Boissé MF, Maison P,Baudic S, Ribeiro MJ, Bourdet C, Remy P, Cesaro P, Hantraye P, Peschanski M.</AU>
<TI>Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: a long-term follow-up study</TI>
<SO>Lancet Neurology</SO>
<YR>2006</YR>
<VL>5(4)</VL>
<PG>303-309</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beister-A" NAME="Beister A" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beister A, Kraus P, Kuhn W, Dose M, Weindl A, Gerlach M</AU>
<TI>The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease</TI>
<SO>J Neural Transm Suppl</SO>
<YR>2004</YR>
<VL>68</VL>
<PG>117 - 22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bender-A" NAME="Bender A" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bender A, Auer DP, Merl T, Reilmann R, Saemann P, Yassouridis A, Bender J, Weindl A, Dose M, Gasser T, Klopstock T</AU>
<TI>Creatine supplementation lowers brain glutamate levels in Huntington's disease</TI>
<SO>J Neurol.</SO>
<YR>2005</YR>
<VL>252(1)</VL>
<PG>36-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bloch-J" NAME="Bloch J" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bloch J, Bachoud-Lévi AC, Déglon N, Lefaucheur JP, Winkel L, Palfi S, Nguyen JP, Bourdet C, Gaura V, Remy P, Brugières P, Boisse MF, Baudic S, Cesaro P, Hantraye P, Aebischer P, Peschanski M</AU>
<TI>Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study</TI>
<SO>Hum Gene Ther</SO>
<YR>2004</YR>
<VL>15(10)</VL>
<PG>968-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bonelli-RM-_x0028_a_x0029_" NAME="Bonelli RM (a)" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bonelli RM, Heuberger C, Reisecker F</AU>
<TI>Minocycline for Huntington's disease: an open label study</TI>
<SO>Neurology.</SO>
<YR>2003</YR>
<VL>60(5)</VL>
<PG>883-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bonelli-RM-_x0028_b_x0029_" NAME="Bonelli RM (b)" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bonelli RM, Hödl AK, Hofmann P, Kapfhammer HP</AU>
<TI>Neuroprotection in Huntington's disease: a 2-year study on minocycline</TI>
<SO>Int Clin Psychopharmacol</SO>
<YR>2004</YR>
<VL>19(6)</VL>
<PG>337-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caro-A" NAME="Caro A" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caro A, Caro S</AU>
<TI>Vitamin E in treatment of Huntington's chorea</TI>
<SO>Br Med J</SO>
<YR>1978</YR>
<VL>1(6116)</VL>
<PG>859</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dubinsky-R" NAME="Dubinsky R" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dubinsky R, Gray C</AU>
<TI>CTYE-I-HD: phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's disease</TI>
<SO>Mov Disord</SO>
<YR>2006</YR>
<VL>21(4)</VL>
<PG>530-533.</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feigin-A" NAME="Feigin A" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feigin A, Kieburtz K, Como P, Hickey C, Claude K, Abwender D, Zimmerman C,Steinberg K, Shoulson I</AU>
<TI>Assessment of coenzyme Q10 tolerability in Huntington's disease</TI>
<SO>Mov Disord</SO>
<YR>1996</YR>
<VL>11(3)</VL>
<PG>312-323</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fink-JS" MODIFIED="2008-11-12 01:12:07 +0000" MODIFIED_BY="[Empty name]" NAME="Fink JS" YEAR="2000">
<REFERENCE MODIFIED="2008-11-12 01:12:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fink JS, Schumacher JM, Ellias SL, Palmer EP, Saint-Hilaire M, Shannon K, Penn R,Starr P, VanHorne C, Kott HS, Dempsey PK, Fischman AJ, Raineri R, Manhart C,Dinsmore J, Isacson O.</AU>
<TI>Porcine xenografts in Parkinson's disease and Huntington's disease patients:preliminary results</TI>
<SO>Cell Transplant</SO>
<YR>2000</YR>
<VL>9</VL>
<NO>2</NO>
<PG>273-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hauser-RA" NAME="Hauser RA" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hauser RA, Furtado S, Cimino CR, Delgado H, Eichler S, Schwartz S, Scott D, Nauert GM, Soety E, Sossi V, Holt DA, Sanberg PR, Stoessl AJ, Freeman TB</AU>
<TI>Bilateral human fetal striatal transplantation in Huntington's disease</TI>
<SO>Neurology</SO>
<YR>2002</YR>
<VL>58(5)</VL>
<PG>687-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Puri-BK-_x0028_b_x0029_" NAME="Puri BK (b)" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Puri BK, Bydder GM, Counsell SJ, Corridan BJ, Richardson AJ, Hajnal JV, Appel C, Mckee HM, Vaddadi KS, Horrobin DF</AU>
<TI>MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment</TI>
<SO>Neuroreport.</SO>
<YR>2002</YR>
<VL>13(1)</VL>
<PG>123-6.</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosas-HD" NAME="Rosas HD" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosas HD, Koroshetz WJ, Jenkins BG, Chen YI, Hayden DL, Beal MF, Cudkowicz ME</AU>
<TI>Riluzole therapy in Huntington's disease (HD)</TI>
<SO>Mov Disord</SO>
<YR>1999</YR>
<VL>14(2)</VL>
<PG>326-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tabrizi-SJ-_x0028_a_x0029_" MODIFIED="2008-12-04 04:41:27 +0000" MODIFIED_BY="[Empty name]" NAME="Tabrizi SJ (a)" YEAR="2003">
<REFERENCE MODIFIED="2008-12-04 04:41:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tabrizi SJ, Blamire AM, Manners DN, Rajagopalan B, Styles P, Schapira AH, Warner TT</AU>
<TI>Creatine therapy for Huntington's disease: clinical and MRS findings in a 1-year pilot study</TI>
<SO>Neurology</SO>
<YR>2003</YR>
<VL>Jul 8;61(1)</VL>
<PG>141-2.</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tabrizi-SJ-_x0028_b_x0029_" NAME="Tabrizi SJ (b)" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tabrizi SJ, Blamire AM, Manners DN, Rajagopalan B, Styles P, Schapira AH, Warner TT</AU>
<TI>High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study</TI>
<SO>Neurology</SO>
<YR>2005</YR>
<VL>64(9)</VL>
<PG>1655-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thomas-M" NAME="Thomas M" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thomas M, Ashizawa T, Jankovic J</AU>
<TI>Minocycline in Huntington´s disease: a pilot study</TI>
<SO>Movement disorders</SO>
<YR>2004</YR>
<VL>20</VL>
<NO>4</NO>
<PG>510-511</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2008-11-08 06:37:23 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-DIMOND" MODIFIED="2008-11-08 06:37:23 +0000" MODIFIED_BY="[Empty name]" NAME="DIMOND" YEAR="2007">
<IDENTIFIERS MODIFIED="2008-11-08 06:37:23 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-08 06:37:23 +0000" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00497159"/>
</IDENTIFIERS>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2008-11-08 06:36:15 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-_x0032_CARE" MODIFIED="2008-11-08 06:35:18 +0000" MODIFIED_BY="[Empty name]" NAME="2CARE" YEAR="">
<IDENTIFIERS MODIFIED="2008-11-08 06:35:12 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-08 06:35:12 +0000" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00608881"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DOMINO" MODIFIED="2008-11-08 06:36:15 +0000" MODIFIED_BY="[Empty name]" NAME="DOMINO" YEAR="2007">
<IDENTIFIERS MODIFIED="2008-11-08 06:36:15 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-08 06:36:15 +0000" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00277355"/>
</IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-01-19 03:40:22 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2009-01-19 03:40:22 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Bonelli-2004" NAME="Bonelli 2004" TYPE="JOURNAL_ARTICLE">
<AU>Bonelli, RM, Wenning GK and Kapfhammer HP</AU>
<TI>Huntington's disease: present treatments and future therapeutic modalities</TI>
<SO>Int Clin Psychopharmacol</SO>
<YR>2004</YR>
<VL>19 (2)</VL>
<PG>51-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cochrane-2008" MODIFIED="2008-12-04 04:37:11 +0000" MODIFIED_BY="[Empty name]" NAME="Cochrane 2008" TYPE="OTHER">
<SO>www.cochrane.org/resources/handbook</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-HSG-1996" MODIFIED="2008-11-08 03:36:56 +0000" MODIFIED_BY="[Empty name]" NAME="HSG 1996" TYPE="JOURNAL_ARTICLE">
<AU>Huntington Study Group</AU>
<TI>Unified Huntington's disease rating scale: Reliability and consistency</TI>
<SO>Movement Disorders</SO>
<YR>1996</YR>
<VL>11</VL>
<NO>2</NO>
<PG>136-42</PG>
<IDENTIFIERS MODIFIED="2008-11-08 03:36:56 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-08 03:36:56 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/mds.870110204"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ</AU>
<TI>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</TI>
<SO>Control Clin Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>(1)</NO>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kieburtz-1994" NAME="Kieburtz 1994" TYPE="JOURNAL_ARTICLE">
<AU>Kieburtz, K. et al</AU>
<TI>Trinucleotide repeat length and progression of illness in Huntington's disease</TI>
<SO>J Med Genet,</SO>
<YR>1994</YR>
<VL>1 (11)</VL>
<PG>872-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lanska-1995" NAME="Lanska 1995" TYPE="JOURNAL_ARTICLE">
<AU>Lanska, DJ</AU>
<TI>George Huntington and hereditary chorea</TI>
<SO>J Child Neurol</SO>
<YR>1995</YR>
<VL>10 (1)</VL>
<PG>46-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Miraxion_x002d_Europe" MODIFIED="2009-01-19 03:40:22 +0000" MODIFIED_BY="[Empty name]" NAME="Miraxion-Europe" TYPE="CONFERENCE_PROC">
<AU>European Huntingotn Disease Network</AU>
<SO>World Congress in Huntington's disease</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Paulsen-JS" MODIFIED="2008-12-04 04:41:11 +0000" MODIFIED_BY="[Empty name]" NAME="Paulsen JS" TYPE="JOURNAL_ARTICLE">
<AU>Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, Guttman M, Johnson S, McDonald M, Beglinger LJ, Duff K, Kayson E, Biglan K, Shoulson I, Oakes D, Hayden M</AU>
<TI>Detection of Huntington's disease decades before diagnosis: The Predict HD study</TI>
<SO>J Neurol Neurosurg Psychiatry</SO>
<YR>2008</YR>
<VL>79</VL>
<NO>8</NO>
<PG>874-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Revman-2008" MODIFIED="2008-11-08 06:16:59 +0000" MODIFIED_BY="[Empty name]" NAME="Revman 2008" TYPE="OTHER">
<AU>Review Manager (RevMan) [MacOSX]. Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008</AU>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ropper-2005" MODIFIED="2008-12-04 04:40:32 +0000" MODIFIED_BY="[Empty name]" NAME="Ropper 2005" TYPE="BOOK">
<AU>Ropper AH, Brown RH</AU>
<SO>Principles of Neurology</SO>
<YR>2005</YR>
<EN>8th ed</EN>
<PB>McGraw-Hill</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-TH-s-DCR-Group-1993" NAME="TH s DCR Group 1993" TYPE="JOURNAL_ARTICLE">
<AU>Group,TH.s.DCR</AU>
<TI>A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosome</TI>
<SO>Cell</SO>
<YR>1993</YR>
<VL>72</VL>
<PG>971-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-TRACK_x002d_HD" NAME="TRACK-HD" TYPE="OTHER">
<TI>http://www.track-hd.net</TI>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-TREND_x002d_HD" MODIFIED="2008-12-04 04:38:44 +0000" MODIFIED_BY="[Empty name]" NAME="TREND-HD" TYPE="CONFERENCE_PROC">
<AU>The Huntington Study group</AU>
<TI>TREND-HD - A Trial of Ethyl-EPA (Miraxion&#8482;) in Treating Mild to Moderate Huntington's Disease</TI>
<SO>World Congress in Huntington's disease</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-04-26 13:12:42 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-04-26 13:08:01 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-04-11 22:17:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-CARE_x002d_HD">
<CHAR_METHODS MODIFIED="2009-04-11 22:13:59 +0100" MODIFIED_BY="[Empty name]">
<P>120-week double-blind, four-arm parallel study. Method of randomisation: computer generated stratification by investigator.<BR/>Results presented for each arm of the trial.<BR/>Intention-to-treat data analysis.<BR/>Location: 25 centres (USA).<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-11 22:17:18 +0100" MODIFIED_BY="[Empty name]">
<P>347 patients, 37 drop-outs. 176 male and 171 female patients completed the trial.<BR/>Mean age of participants: 47.9±10,5 years.<BR/>Mean duration of disease: 4,9±3,1 years.<BR/>Inclusion criteria: HD (genetically established or positive family history) TFC-UHDRS&#8805;7, disease stage I or II.<BR/>Exclusion criteria: Coenzyme Q10 use in previous 3 months, unstable medical or psychiatric disease.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Coenzyme Q10, 300-600mg/day (87 patients), remacemide, 400-600mg/day (86 patients) or Coenzyme Q10+remacemide , 300-600mg/day+400-600mg/day (87 patients) and placebo - identical pills (87 patients). No titration.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-11 22:16:02 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: deteriorarion in TFC-UHDRS.</P>
<P>Secondary: </P>
<UL>
<LI>Change in TMS-UHDRS.</LI>
</UL>
<UL>
<LI>Change in cognitive function (Stroop test, Hopkins Verbal Learning Test, Brief Test Attention, Conditional Associative Learning Test, Trailmaking test, Test for visuomotor speed).</LI>
<LI>Frequency and severity of individual adverse events, abnormal values or changes of laboratory tests and ECG results, changes from baseline to 30 months in laboratory test and vital signs.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Negative for efficacy measures.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-04-11 22:19:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-EHDN">
<CHAR_METHODS MODIFIED="2009-04-11 22:18:34 +0100" MODIFIED_BY="[Empty name]">
<P>144-week double-blind, unbalanced parallel study (treatment:placebo - 2:1). Method of randomisation: computer generated stratification by centre.<BR/>Results presented for each arm of the trial.<BR/>Intention-to-treat and per-protocol data analysis.<BR/>Location: 44 centres (Europe).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-11 22:18:48 +0100" MODIFIED_BY="[Empty name]">
<P>537 patients with 158 drop-outs. 271 male and 266 female patients.<BR/>Mean age of participants: 45,5±9.7 years.<BR/>Mean duration of disease: 5,5±4.4 years.<BR/>Inclusion criteria: adult (25-65 years old), genetically established HD, independently ambulatory with a TFC-UHDRS&#8805;8, total motor score-UHDRS&#8805;5, monitor compliance, caregiver to witness consent.<BR/>Exclusion criteria: comorbid or co-medication that would interfere study results, pregnancy, breast-feeding, inadequate contraception, prior exposure to riluzole, contraindication to riluzole, serum markers of hepatic function&gt;2xULN (alanine aminotransferase, aspartate aminotransferase and bilirubin) and anti-choreic medication within 1 month of baseline visit.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-04-11 22:19:45 +0100" MODIFIED_BY="[Empty name]">
<P>Oral Riluzole 100 mg/day (357 patients) and placebo - identical pills - (180 patients). No titration.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-11 22:19:26 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: composite score of TMS-UHDRS and TFC-UHDRS.</P>
<P>Secondary: </P>
<UL>
<LI>TMS-UHDRS.</LI>
<LI>TFC-UHDRS.</LI>
<LI>UHDRS items: chorea score, cognitive, behavioral, functional, independence and global clinical impression subscales.</LI>
<LI>Beck Depression inventory.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-04-11 22:19:32 +0100" MODIFIED_BY="[Empty name]">
<P>Negative for efficacy measures.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-04-26 13:02:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kremer-B">
<CHAR_METHODS MODIFIED="2009-04-26 13:01:56 +0100" MODIFIED_BY="[Empty name]">
<P>120-week double-blind, parallel study. Method of randomisation: stratification by age and gender.</P>
<P>Results presented for each arm of the trial.<BR/>Intention-to-treat data analysis.<BR/>Location: 7 centres (Canada).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-26 13:02:13 +0100" MODIFIED_BY="[Empty name]">
<P>64 patients, 9 drop-outs. 23 male and 32 female patients completed the trial.<BR/>Mean age of participants: 44,7± 3,8 years.<BR/>Mean duration of disease: 2,9 ±0.7 years.<BR/>Inclusion criteria: HD diagnosis defined by the appearance of motor abnormalities, disease duration&lt;5 years, presence of neurological abnormalities (e.g., chorea, gait abnormalities, dysarthria) and expanded CAG repeat.<BR/>Exclusion criteria: heart, kidney or liver disease, Diabetes Mellitus, unable to cope cognitively with trial requirements, &lt;18 years, use of antidepressants or neuroleptics, ongoing depression or psychosis on recruitment.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-04-11 22:26:26 +0100" MODIFIED_BY="[Empty name]">
<P>Oral Lamotrigine 400 mg/day (maximum), increase every 2 weeks for 12 weeks (no dosage described) (33 patients) and placebo (31 patients).<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-11 22:25:12 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: Change in TFC-UHDRS.<BR/>Secondary:</P>
<UL>
<LI>Change in QNE.</LI>
<LI>Change in Cognitive function (MMSE, WAIS-R, WMS, Paired associates, paragraph recall, word fluency tests).</LI>
<LI>Change in motor function (Klove Grooved Pegboard, Finger Tapping test).</LI>
<LI>PET scanning (PET- deoxyglucose).</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-04-11 22:24:22 +0100" MODIFIED_BY="[Empty name]">
<P>Negative for efficacy measures.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-04-26 13:05:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peyser-CE">
<CHAR_METHODS MODIFIED="2009-04-11 22:28:23 +0100" MODIFIED_BY="[Empty name]">
<P>52-week double-blind, parallel study. Method of randomisation: random number table.<BR/>Results presented for each arm of the trial.<BR/>Per-protocol data analysis.<BR/>Location: 1 centre (USA).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-11 22:28:26 +0100" MODIFIED_BY="[Empty name]">
<P>81 patients, 8 drop-outs.<BR/>Mean age of participants: no data.<BR/>Mean duration of disease: no data.<BR/>Inclusion criteria: HD (clinical diagnosis and positive family history), mild to moderate disease (mild to moderate dementia, MMSE&gt;15, ambulatory care), reliable family member for information and medication compliance.<BR/>Exclusion criteria: none stated.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-04-11 22:29:14 +0100" MODIFIED_BY="[Empty name]">
<P>Oral Vitamin E 3000 UI/day (40 patients) and placebo, identical capsules (33 patients). No titration.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-11 22:29:26 +0100" MODIFIED_BY="[Empty name]">
<P>Change in quality of life (ADL scale of the Baltimore HD project).<BR/>Change in motor abnormalities (QNE).<BR/>Change in cognitive function (MMSE, digit span, Controlled Oral Word Association Test, Design Fluency Test, Trail Making Test, CERAD Verbal Learning Test, Luria Sequential Hand Position Test, Wisconsin Card Sorting Test, Benton Visual Retention Test, Motor Go/No-Go Test, Stroop Word Test).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-04-26 13:05:06 +0100" MODIFIED_BY="[Empty name]">
<P>Negative for efficacy measures. Post-hoc analysis produced positive results for patients with QNE&lt;45.<BR/>All patients were given anti-oxidants vitamin A and C.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-04-11 22:31:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Puri-BK">
<CHAR_METHODS MODIFIED="2009-04-11 22:29:33 +0100" MODIFIED_BY="[Empty name]">
<P>52-week double-blind, parallel study. Method of randomisation: stratified by blocks of four.<BR/>Results presented for each arm of the trial.<BR/>Intention-to-treat and per-protocol data analysis.<BR/>Location: 6 centres (USA and Canada).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-11 22:31:15 +0100" MODIFIED_BY="[Empty name]">
<P>135 patients with 14 drop-outs. 68 male and 67 female patients completed the trial.<BR/>Mean age of participants: 49,5±9,1 years.<BR/>Mean duration of disease: no data.<BR/>Inclusion criteria: symptomatic HD genetically confirmed or with family history of HD. Functional stage I/II. Independence scale score of 50 - 90. Available caregiver between 30 and 70 years of age.<BR/>Exclusion criteria: depot neuroleptics.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oral Ethyl-EPA 2g/day (67 patients) and placebo - identical pills (68 patients). No titration.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-11 22:31:45 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: TMS-4 score (UHDRS) at 12 months.<BR/>Secondary:</P>
<UL>
<LI>Change in TMS-UHDRS.</LI>
<LI>Change in TMS-4 score (motor-UHDRS) at 6 months.</LI>
<LI>Change in UHDRS (cognitive, behavioral, functional scales).</LI>
<LI>Change in Rockland Simpson Dysknesia Score.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-04-11 22:29:49 +0100" MODIFIED_BY="[Empty name]">
<P>Negative for efficacy measures.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-04-11 22:33:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ranen-NG">
<CHAR_METHODS MODIFIED="2009-04-11 22:32:35 +0100" MODIFIED_BY="[Empty name]">
<P>52-week double-blind, parallel study. Method of randomisation: not stated.<BR/>Results presented for each arm of the trial.<BR/>Intention-to-treat data analysis.<BR/>Location: 1 centre (USA).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-11 22:33:08 +0100" MODIFIED_BY="[Empty name]">
<P>100 patients, 9 drop-outs. 44 male and 47 female patients (per-protocol cohort).<BR/>Mean age of participants: 42.1±11.7 years.<BR/>Mean age of disease onset: 5,0±0.4 years.<BR/>Inclusion criteria: mild-moderate HD (family history, chorea/rigidity, MMSE&gt;14), relative or companion to serve as informant and to supervise medication.<BR/>Exclusion criteria: current major depression, other CNS disease, active medical illness, alcohol or substance abuse, psychosis, MRI evidence of striatal infarction. CNS-acting medication (antipsychotics, CoQ, vitamin E, BZD, barbiturics, antioxidants, CNS-acting antihypertensives), except stable use of nortriptyline (depression) and carbamazepine (mania or irritability), chloral hydrate up to twice a week (sleep), but not within 72h of screening/visits.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oral Idebenone 270 mg/day (48 patients) and placebo, identical pills (43 patients). No titration.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-11 22:33:43 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: Change in the composite of ADL-UHDRS and QNE (chorea, eye movement, motor impairment scales).<BR/>Secondary:</P>
<UL>
<LI>Change in cognitive function (MMSE).</LI>
<LI>Change in neuropsychiatric performance (Buschke Selective Reading test, Benton Visual Retention test, Grooved Pegboard, Wechsler Adult Intelligence Scale, Trail Making test, Stroop test).</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-04-11 22:33:50 +0100" MODIFIED_BY="[Empty name]">
<P>Negative for efficacy measures.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-04-11 22:34:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shoulson-I">
<CHAR_METHODS MODIFIED="2009-01-12 17:36:22 +0000" MODIFIED_BY="[Empty name]">
<P>30-week double-blind, in parallel study (12 weeks follow-up). Method of randomisation: stratification by age and stage of ilness.<BR/>Results presented for each arm of the trial.<BR/>Per-protocol data analysis.<BR/>Location: 1 centre (USA).<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-11 22:34:58 +0100" MODIFIED_BY="[Empty name]">
<P>60 patients, 11 drop-outs. 24 male patients and 25 female patients.<BR/>Mean age of participants: 39,4±10.4 years.<BR/>Mean duration of disease: 5,3± 3.3 years.<BR/>Inclusion criteria: HD (unexplained movement disorder and positive family history), &gt;18 years of age, early stage disease (functional stages I-II), satisfactory general medical health, person for support and company.<BR/>Exclusion criteria: serious psychiatric illness (major depression with antidepressant medication, psychotic illness requiring antipsychotics, active suicidal behavior).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Ora Baclofen 60 mg/day (30 patients) and placebo (30 patients). No titration.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-11 22:34:34 +0100" MODIFIED_BY="[Empty name]">
<P>Change in mTFC-UHDRS.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-04-11 22:34:27 +0100" MODIFIED_BY="[Empty name]">
<P>Negative for efficacy measures.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-04-11 22:36:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Verbessem-P">
<CHAR_METHODS MODIFIED="2009-04-11 22:35:27 +0100" MODIFIED_BY="[Empty name]">
<P>52-week double-blind, in parallel study. Method of randomisation: unbalanced randomisation (Creatine:Placebo - 2:1). Full random allocation was not possible.<BR/>Results presented for each arm of the trial.<BR/>Intention-to-treat data analysis.<BR/>Location: 1 centre (Belgium).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-11 22:35:29 +0100" MODIFIED_BY="[Empty name]">
<P>42 patients, 3 drop-outs. 15 male and 26 female patients completed the trial.<BR/>Mean age of participants: 49,8±2,2 years.<BR/>Mean duration of disease: 8,0±1,5 years.<BR/>Inclusion criteria: HD (genetic diagnosis), functional stages I-III, stable medication for at least 3 months.<BR/>Exclusion criteria: history of renal pathology, existing albuminuria, prior creatine use.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oral Creatine 5 g/day (87 patients) and placebo, identical in appearance and taste (30 patients). No titration.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-11 22:36:09 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: change in static and dynamic force.<BR/>Secondary:</P>
<UL>
<LI>Change in UHDRS items.</LI>
<LI>Change in cardiorespiratory fitness.</LI>
<LI>Change in bimanual coordination skill.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-04-11 22:35:41 +0100" MODIFIED_BY="[Empty name]">
<P>Negative for efficacy measures.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ADL - Activities of daily living.<BR/>BZD - Benzodiazepine.<BR/>CAG - Glutamine.<BR/>CERAD - Consortium to Establish a Registry for Alzheimer&#8217;s Disease.<BR/>CNS - Central Nervous System.<BR/>EPA - Eicosapentaenoic acid.<BR/>HD -Huntington's disease.<BR/>MMSE - Mini-Mental State Examination.<BR/>MRI - Magnetic Ressonance Imaging.<BR/>mTFC - modified Total Functioning Capacity.<BR/>PET - Positron Emission Tomography.<BR/>QNE - Quantified Neurological Examination.<BR/>TFC - Total Functioning Capacity.<BR/>TMS - Total Motor Score.<BR/>UHDRS -Unified Huntington Disease Revised Scale.<BR/>WAIS-R - Wechsler Adult Intelligence Scale-revised.</P>
<P>WMS - Wechsler Memory Scale.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-01-12 17:10:46 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Bachoud_x002d_L_x00e9_vi-AC-_x0028_a_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bachoud_x002d_L_x00e9_vi-AC-_x0028_b_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bachoud_x002d_L_x00e9_vi-AC-_x0028_c_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Beister-A">
<CHAR_REASON_FOR_EXCLUSION>
<P>open-label study<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bender-A">
<CHAR_REASON_FOR_EXCLUSION>
<P>open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bloch-J">
<CHAR_REASON_FOR_EXCLUSION>
<P>phase I study<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bonelli-RM-_x0028_a_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>open-label study<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bonelli-RM-_x0028_b_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>open-label study<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-01-12 17:10:46 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Caro-A">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-01-12 17:10:46 +0000" MODIFIED_BY="[Empty name]">
<P>Crossover</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dubinsky-R">
<CHAR_REASON_FOR_EXCLUSION>
<P>phase I study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Feigin-A">
<CHAR_REASON_FOR_EXCLUSION>
<P>open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-12 01:13:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fink-JS">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-12 01:13:31 +0000" MODIFIED_BY="[Empty name]">
<P>open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hauser-RA">
<CHAR_REASON_FOR_EXCLUSION>
<P>non-controlled</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Puri-BK-_x0028_b_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>n&lt;10<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rosas-HD">
<CHAR_REASON_FOR_EXCLUSION>
<P>open-label study<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tabrizi-SJ-_x0028_a_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tabrizi-SJ-_x0028_b_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Thomas-M">
<CHAR_REASON_FOR_EXCLUSION>
<P>open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2009-04-26 13:10:30 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2009-04-26 13:10:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-DIMOND">
<CHAR_METHODS MODIFIED="2009-04-26 13:09:49 +0100" MODIFIED_BY="[Empty name]">
<P>12-week, randomised, double-blind, parallel study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-26 13:09:52 +0100" MODIFIED_BY="[Empty name]">
<P>90 HD patients (clinical features of HD and a confirmatory family history of HD, and/or genetically confirmed HD), able to take medication (capsules) by mouth. </P>
<P>Exclusion criteria: unstable medical illness, pregnant or lactating women of those intending to become pregnant during the study period.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-04-26 13:10:26 +0100" MODIFIED_BY="[Empty name]">
<P>Dimebon 60 mg/day vs placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-26 13:10:30 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: safety and tolerability.</P>
<P>Secondary endpoint: efficacy on cognitive, motor, and overall function in subjects with Huntington's Disease. Assess the pharmacokinetics of Dimebon.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-08 06:29:15 +0000" MODIFIED_BY="[Empty name]"/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2009-04-26 13:12:42 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2009-04-26 13:12:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x0032_CARE">
<CHAR_STUDY_NAME MODIFIED="2009-04-11 22:39:09 +0100" MODIFIED_BY="[Empty name]">
<P>Coenzyme Q10 in Huntington's Disease.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-04-26 13:10:56 +0100" MODIFIED_BY="[Empty name]">
<P>5-year randomised, double-blind, parallel study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-26 13:11:07 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical features of HD and confirmatory family history of HD and/or genetically confirmed HD. &#8805;16 years of age.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-04-26 13:12:42 +0100" MODIFIED_BY="[Empty name]">
<P>Coenzyme Q10 2400 mg/day vs placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-26 13:11:42 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: change in total functional capacity.</P>
<P>Secondary: change in other UHDRS scores, tolerability and safety, time to decline in TFC by 2 and 3 points.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-04-26 13:11:55 +0100" MODIFIED_BY="[Empty name]">
<P>March 2008.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-04-26 13:11:56 +0100" MODIFIED_BY="[Empty name]">
<P>Huntington Study Group (1-800-487-7671).</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-04-26 13:12:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-DOMINO">
<CHAR_STUDY_NAME MODIFIED="2009-04-26 13:12:02 +0100" MODIFIED_BY="[Empty name]">
<P>A Multi-Center, Double-Blind, Pilot Study of Minocycline in Huntington's Disease.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-04-26 13:12:14 +0100" MODIFIED_BY="[Empty name]">
<P>18-month, randomised, double-blind, parallel study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-26 13:12:27 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical features of HD and a confirmatory family history of HD and/or genetically confirmed HD. 18 years or older.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-04-26 13:12:39 +0100" MODIFIED_BY="[Empty name]">
<P>Minocycline 200 mg/day vs. placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-11 22:47:14 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: change in TFC-UHDRS, and to assess futility of further study of the drug.</P>
<P>Secondary: safety/tolerability.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-04-26 13:12:06 +0100" MODIFIED_BY="[Empty name]">
<P>January 2006.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-04-26 13:12:07 +0100" MODIFIED_BY="[Empty name]">
<P>Huntington Study Group (1-800-487-7671).</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2009-04-11 22:47:11 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-CARE_x002d_HD">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-EHDN">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Kremer-B">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Peyser-CE">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Puri-BK">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ranen-NG">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Shoulson-I">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Verbessem-P">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2009-04-26 13:13:03 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2009-04-26 13:13:03 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-11-08 03:17:56 +0000" MODIFIED_BY="[Empty name]">Unified Huntington's Disease Rating Scale (UHDRS)</TITLE>
<TABLE COLS="2" ROWS="6">
<TR>
<TD>
<P>
<B>COMPONENTS</B>
</P>
</TD>
<TD>
<P>
<B>domains evaluated</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Motor Assessment<BR/>
</P>
</TD>
<TD>
<P>oculomotor function, dysarthria, chorea, dystonia, gait, postural stability.</P>
</TD>
</TR>
<TR>
<TD>
<P>Cognitive Assessment<BR/>
</P>
</TD>
<TD>
<P>phonetic verbal fluency test, Symbol Digit Modalities Test, the Stroop Test.</P>
</TD>
</TR>
<TR>
<TD>
<P>Behavioral Assessment<BR/>
</P>
</TD>
<TD>
<P>affect, thought content, coping styles.</P>
</TD>
</TR>
<TR>
<TD>
<P>Functional Assessment<BR/>
</P>
</TD>
<TD>
<P>Independence Scale (checklist of common daily tasks), Total Functional Capacity (TFC).</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>
<LINK REF="REF-HSG-1996" TYPE="REFERENCE">HSG 1996</LINK>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES MODIFIED="2008-12-04 04:45:39 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Untitled.jpg" FILE_TYPE="JPG" ID="FIG-01" MODIFIED="2008-12-04 04:45:39 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2009-01-12 15:13:05 +0000" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2009-01-12 15:13:05 +0000" MODIFIED_BY="[Empty name]"/>
<EXTENSIONS MODIFIED="2009-01-12 15:13:05 +0000" MODIFIED_BY="[Empty name]"/>
</COCHRANE_REVIEW>